BG62877B1 - Метод за контрол на женски фертилитет - Google Patents
Метод за контрол на женски фертилитет Download PDFInfo
- Publication number
- BG62877B1 BG62877B1 BG101427A BG10142797A BG62877B1 BG 62877 B1 BG62877 B1 BG 62877B1 BG 101427 A BG101427 A BG 101427A BG 10142797 A BG10142797 A BG 10142797A BG 62877 B1 BG62877 B1 BG 62877B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- phenyl
- hydroxy
- methyl
- competitive progesterone
- hydroxyprop
- Prior art date
Links
- 230000035558 fertility Effects 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 13
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 239000000044 progesterone antagonist Substances 0.000 claims abstract description 41
- 230000002860 competitive effect Effects 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000027758 ovulation cycle Effects 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 11
- -1 4-acetylphenyl Chemical group 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- JFEPJTGMGDGPHJ-PNKHAZJDSA-N (8r,9s,10r,13s,14s)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 JFEPJTGMGDGPHJ-PNKHAZJDSA-N 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000016087 ovulation Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000006187 pill Substances 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 15
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002513 implantation Methods 0.000 description 10
- 229950011093 onapristone Drugs 0.000 description 10
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 230000002357 endometrial effect Effects 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000029849 luteinization Effects 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 230000002254 contraceptive effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000288906 Primates Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940127234 oral contraceptive Drugs 0.000 description 3
- 239000003539 oral contraceptive agent Substances 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003418 antiprogestin Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 231100000546 inhibition of ovulation Toxicity 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000011599 ovarian follicle development Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000006018 1-methyl-ethenyl group Chemical group 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GSSFKPLLVATOAZ-ITGMQTRRSA-N C1CC2CC(=O)CC[C@@H]2[C@H]3[C@@H]1[C@@H]4CC=CC4=CC3 Chemical compound C1CC2CC(=O)CC[C@@H]2[C@H]3[C@@H]1[C@@H]4CC=CC4=CC3 GSSFKPLLVATOAZ-ITGMQTRRSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 206010033310 Ovulation delayed Diseases 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4438820 | 1994-10-24 | ||
| PCT/EP1995/004191 WO1996012494A1 (de) | 1994-10-24 | 1995-10-24 | Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG101427A BG101427A (en) | 1997-11-28 |
| BG62877B1 true BG62877B1 (bg) | 2000-10-31 |
Family
ID=6532105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG101427A BG62877B1 (bg) | 1994-10-24 | 1997-04-21 | Метод за контрол на женски фертилитет |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6143754A (cs) |
| EP (1) | EP0787002B1 (cs) |
| JP (1) | JPH10507461A (cs) |
| KR (1) | KR970706827A (cs) |
| CN (1) | CN1211087C (cs) |
| AT (1) | ATE347894T1 (cs) |
| AU (1) | AU707235B2 (cs) |
| BG (1) | BG62877B1 (cs) |
| BR (1) | BR9509478A (cs) |
| CA (1) | CA2203541A1 (cs) |
| CZ (1) | CZ290690B6 (cs) |
| DE (1) | DE59511071D1 (cs) |
| DK (1) | DK0787002T3 (cs) |
| ES (1) | ES2279515T3 (cs) |
| FI (1) | FI971742A7 (cs) |
| HU (1) | HU226566B1 (cs) |
| IL (1) | IL115738A (cs) |
| NO (1) | NO314437B1 (cs) |
| NZ (1) | NZ295365A (cs) |
| PL (1) | PL319869A1 (cs) |
| PT (1) | PT787002E (cs) |
| RO (1) | RO120606B1 (cs) |
| SK (1) | SK283662B6 (cs) |
| WO (1) | WO1996012494A1 (cs) |
| ZA (1) | ZA959008B (cs) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19745085A1 (de) * | 1997-10-11 | 1999-04-15 | Jenapharm Gmbh | 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
| DE19809845A1 (de) | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| CO5190694A1 (es) * | 1999-08-31 | 2002-08-29 | Jenapharm Gmbh And Co Kg | Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos |
| US7629334B1 (en) | 1999-08-31 | 2009-12-08 | Bayer Schering Pharma Aktiengesellschaft | Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT) |
| UA75339C2 (en) * | 1999-08-31 | 2006-04-17 | Schering Ag | Use of mesoprogestins (progesterone receptor modulators) as pharmaceutical components for manufacture of medicament for hormone replacement therapy (hrt) |
| DE102005050729A1 (de) * | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
| US20090170823A1 (en) * | 2007-12-20 | 2009-07-02 | Duramed Pharmaceuticals, Inc. | Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception |
| NZ615430A (en) | 2009-04-14 | 2014-06-27 | Laboratoire Hra-Pharma | Method for on-demand contraception |
| CA2758764C (en) * | 2009-04-14 | 2017-04-11 | Elizabeth Gray Raymond | Method for on-demand contraception using levonorgestrel or norgestrel |
| CA2913085A1 (en) | 2013-05-23 | 2014-11-27 | Bernhard Lindenthal | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception |
| HK1246653A1 (zh) | 2014-11-17 | 2018-09-14 | Context Biopharma Inc. | 奧那司酮延長釋放組合物和方法 |
| JP2018528944A (ja) | 2015-09-25 | 2018-10-04 | コンテクスト バイオファーマ インコーポレイテッド | オナプリストン中間体の製造方法 |
| MX2018007154A (es) | 2015-12-15 | 2019-01-10 | Context Biopharma Inc | Composiciones de onapristona amorfa y metodos para hacer las mismas. |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439913A (en) * | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
-
1995
- 1995-10-24 BR BR9509478A patent/BR9509478A/pt active Search and Examination
- 1995-10-24 FI FI971742A patent/FI971742A7/fi unknown
- 1995-10-24 CA CA002203541A patent/CA2203541A1/en not_active Abandoned
- 1995-10-24 HU HU9702177A patent/HU226566B1/hu not_active IP Right Cessation
- 1995-10-24 NZ NZ295365A patent/NZ295365A/xx unknown
- 1995-10-24 AT AT95937845T patent/ATE347894T1/de not_active IP Right Cessation
- 1995-10-24 PT PT95937845T patent/PT787002E/pt unknown
- 1995-10-24 JP JP8513655A patent/JPH10507461A/ja active Pending
- 1995-10-24 CZ CZ19971180A patent/CZ290690B6/cs not_active IP Right Cessation
- 1995-10-24 DE DE59511071T patent/DE59511071D1/de not_active Expired - Fee Related
- 1995-10-24 DK DK95937845T patent/DK0787002T3/da active
- 1995-10-24 CN CNB951958178A patent/CN1211087C/zh not_active Expired - Fee Related
- 1995-10-24 IL IL11573895A patent/IL115738A/en not_active IP Right Cessation
- 1995-10-24 WO PCT/EP1995/004191 patent/WO1996012494A1/de active IP Right Grant
- 1995-10-24 ES ES95937845T patent/ES2279515T3/es not_active Expired - Lifetime
- 1995-10-24 AU AU38696/95A patent/AU707235B2/en not_active Ceased
- 1995-10-24 EP EP95937845A patent/EP0787002B1/de not_active Expired - Lifetime
- 1995-10-24 RO RO97-00635A patent/RO120606B1/ro unknown
- 1995-10-24 ZA ZA959008A patent/ZA959008B/xx unknown
- 1995-10-24 PL PL95319869A patent/PL319869A1/xx unknown
- 1995-10-24 SK SK518-97A patent/SK283662B6/sk unknown
-
1997
- 1997-04-21 BG BG101427A patent/BG62877B1/bg unknown
- 1997-04-23 NO NO19971869A patent/NO314437B1/no unknown
- 1997-04-24 KR KR1019970702695A patent/KR970706827A/ko not_active Ceased
-
1999
- 1999-03-22 US US09/273,485 patent/US6143754A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6225297B1 (en) | Combination contraceptive | |
| KR100365879B1 (ko) | 프로게스테론길항제및게스타겐을포함하는자궁내막증식증또는자궁평활근종치료제 | |
| AU710819B2 (en) | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception | |
| US20010027189A1 (en) | Progestogen-anti-progestogen regimens | |
| BG62877B1 (bg) | Метод за контрол на женски фертилитет | |
| US20050064031A1 (en) | Combination contraceptive, kits that contain the latter, and a method that uses the latter | |
| US6642219B1 (en) | Progestogen-antiprogestogen regimens | |
| SK2982002A3 (en) | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives | |
| SK2972002A3 (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
| MXPA97003018A (es) | Antagonistas de progesterona competentes para regular la fertilidad femenina segun se requiera |